HRPMF — Stock activity · TradeandTell
HRPM
HRPMF Held by
0
portfolios on TandT
Avg position size
—
of holders' portfolios
Financials Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
Income Balance sheet Cash flow
2017 2018 2019 2020 2021 2022 2023 2024 $0 $0 $0 $0 $0 $0 $0 $0 $1.2M $1.2M $1.0M $927.7K $0 $0 $0 $0 −$1.2M −$1.2M −$1.0M −$928.0K $0 $0 $0 $0 — — — — — — — — $2.3M $2.1M $4.9M $5.3M $6.2M $5.0M $2.7M $3.6M −$2.2M −$4.9M −$7.2M −$8.1M −$9.1M −$8.0M $154.4K −$5.0M −$638.0K −$2.9M −$6.1M −$7.1M $6.9M $8.0M $831.4K −$4.9M −$2.2M −$4.2M −$8.0M −$9.2M −$23.6M −$9.3M $279.8K −$4.9M — — — — — — — — -0.51 -0.85 -1.30 -1.18 -2.20 -0.64 0.02 -0.24
Annual figures · source: Financial Modeling Prep
Peer comparison Symbol Price Today Mkt cap P/E HRPMF Herantis Pharma Oyj $3.51 +0.00% $59M — BSTG Biostage, Inc. $4.03 +0.75% $58M — DMTTF Small Pharma Inc. $0.11 -9.69% $38M — EEOIF Elegance Optical International Holdings Limited $0.07 +0.00% $63M — GDNSF Goodness Growth Holdings, Inc. $0.45
Held by traders on TradeandTell No one on the platform currently holds HRPMF.
Super investors & insiders Institutions holding (13F)
No tracked institution reports a position in HRPMF as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell No one on the platform has traded HRPMF yet.
Report a bug KDEVF Karolinska Development AB (publ) $0.26 +0.00% $69M —
MSSTF Mindset Pharma Inc. $0.54 -0.37% $55M —
Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$HRPMF chatter on StockTwits $HRPMF According to Herantis, HER-096 is now ready to advance into Phase 2 efficacy studies for Parkinson’s disease.
In Phase 1, the company reported:
strong safety and tolerability
confirmed brain penetration
biological responses in biomarkers consistent with the mechanism of action
In the Phase 1B study, the 300 mg dose was selected for Phase 2 development.
Herantis also received an €8M EU grant for the Phase 2 trial and said partnering discussions are ongoing.
View on StockTwits ↗ $HRPMF https://www.biospace.com/press-releases/inside-information-herantis-pharma-selected-for-horizon-2025-grant-of-eur-8-0-million-for-phase-2-trial-of-her-096?utm_source=chatgpt.com
View on StockTwits ↗ $HRPMF https://parkinsonsnewstoday.com/news/her-096-trial-data-show-early-biological-signals-parkinsons/
View on StockTwits ↗ Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
